1-Pyrazin-2-yl-piperidin-3-ylaminehydrochloride

97%

Reagent Code: #227417
fingerprint
CAS Number 1185319-30-5

science Other reagents with same CAS 1185319-30-5

blur_circular Chemical Specifications

scatter_plot Molecular Information
Weight 214.695 g/mol
Formula C₉H₁₅ClN₄
badge Registry Numbers
MDL Number MFCD09607859
inventory_2 Storage & Handling
Storage Room temperature, seal, dry

description Product Description

Used as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. It serves as a building block in medicinal chemistry due to its ability to enhance binding affinity and selectivity in drug molecules. Commonly employed in research settings for designing new active pharmaceutical ingredients (APIs) targeting neurological and oncological disorders. Its structure supports modification for optimizing pharmacokinetic properties such as solubility and metabolic stability.

Available Sizes & Pricing

Size Availability Unit Price Quantity
500mg
10-20 days ฿40,130.00
1-Pyrazin-2-yl-piperidin-3-ylaminehydrochloride
No image available

Used as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. It serves as a building block in medicinal chemistry due to its ability to enhance binding affinity and selectivity in drug molecules. Commonly employed in research settings for designing new active pharmaceutical ingredients (APIs) targeting neurological and oncological disorders. Its structure supports modification for optimizing pharmacokinetic properties

Used as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. It serves as a building block in medicinal chemistry due to its ability to enhance binding affinity and selectivity in drug molecules. Commonly employed in research settings for designing new active pharmaceutical ingredients (APIs) targeting neurological and oncological disorders. Its structure supports modification for optimizing pharmacokinetic properties such as solubility and metabolic stability.

Mechanism -
Appearance -
Longevity -
Strength -
Storage -
Shelf Life -
Allergen(s) -
Dosage (Range) -
Dosage (Per Day) -
Mix Method -
Heat Resistance -
Stable in pH range -
Solubility -
Product Types -
INCI -

Purchase History for

Loading purchase history...